Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

This study is designed to evaluate the efficacy and safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE as the perioperative adjuvant therapy in surgical resection to hepatocellular carcinoma with high-risk features. (1) Evaluate for some high-risk patients with resectable tumours, whether or not sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE reduces the risk of recurrence and improves the survival of patients. (2) Evaluate the safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE for the neoadjuvant therapy of resectable hepatocellular carcinoma.

NCT Number	NCT07522411
Lead Sponsor	BinYong Liang Collaborators: Beijing Bethune Charitable Foundation
Conditions	Hepatocellular Carcinoma
Enrollment	100 participants
Start Date	2026-04-30
Primary Completion	2027-12 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2026-04-13